Genomic determinants of hepatitis C virus antiviral therapy outcomes: Toward individualized treatment
Cargando...
Archivos
Fecha
2012
Autores
Profesor/a Guía
Facultad/escuela
Idioma
en
Título de la revista
ISSN de la revista
Título del volumen
Editor
Elsevier
Nombre de Curso
Licencia CC
Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Licencia CC
Resumen
Hepatitis C virus (HCV) is an important global health problem with an estimated prevalence of more than 170 million infected individuals worldwide. Currently, the standard antiviral therapy, based on pegylated in-terferon alpha and ribavirin, can achieve a virological response in only nearly 50% of the patients infected with HCV genotype 1, the most widely distributed globally. During the last years, relevant data from geno-me-wide association studies (GWAS) about the impact and contribution of the patient genomics on viral in-fection outcomes has suggested the possibility that an individualized antiviral therapy can be considered. In this review, we analyze the existing information on single nucleotide polymorphisms (SNPs) of several host genes and viral factors that influence, as a whole, the outcome of the standard antiviral therapy, and that might be used to predict an individualized antiviral response. We also discuss the clinical data within the most recent context of the triple antiviral therapy.
Notas
Indexación: Scopus.
Palabras clave
Direct-acting antiviral, Genetic variant, IL28B polymorphisms, Peginterferon/ribavirin treatment, PegiFNalpha/RBV
Citación
Annals of Hepatology Volume 11, Issue 6, Pages 827 - 837, 2012
DOI
10.1016/s1665-2681(19)31407-3